JP7799904B2 - テネリグリプチン含有製剤 - Google Patents

テネリグリプチン含有製剤

Info

Publication number
JP7799904B2
JP7799904B2 JP2025519350A JP2025519350A JP7799904B2 JP 7799904 B2 JP7799904 B2 JP 7799904B2 JP 2025519350 A JP2025519350 A JP 2025519350A JP 2025519350 A JP2025519350 A JP 2025519350A JP 7799904 B2 JP7799904 B2 JP 7799904B2
Authority
JP
Japan
Prior art keywords
teneligliptin
reference example
porous silica
acid
containing particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025519350A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024232216A1 (https=
JPWO2024232216A5 (https=
Inventor
卓朗 西村
晴大 豊田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sawai Pharmaceutical Co Ltd
Original Assignee
Sawai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sawai Pharmaceutical Co Ltd filed Critical Sawai Pharmaceutical Co Ltd
Publication of JPWO2024232216A1 publication Critical patent/JPWO2024232216A1/ja
Publication of JPWO2024232216A5 publication Critical patent/JPWO2024232216A5/ja
Application granted granted Critical
Publication of JP7799904B2 publication Critical patent/JP7799904B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2025519350A 2023-05-10 2024-04-11 テネリグリプチン含有製剤 Active JP7799904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023078027 2023-05-10
JP2023078027 2023-05-10
PCT/JP2024/014708 WO2024232216A1 (ja) 2023-05-10 2024-04-11 テネリグリプチン含有製剤

Publications (3)

Publication Number Publication Date
JPWO2024232216A1 JPWO2024232216A1 (https=) 2024-11-14
JPWO2024232216A5 JPWO2024232216A5 (https=) 2025-10-08
JP7799904B2 true JP7799904B2 (ja) 2026-01-15

Family

ID=93430149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025519350A Active JP7799904B2 (ja) 2023-05-10 2024-04-11 テネリグリプチン含有製剤

Country Status (4)

Country Link
JP (1) JP7799904B2 (https=)
CN (1) CN119300831A (https=)
TW (1) TWI896097B (https=)
WO (1) WO2024232216A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209350A1 (ja) 2019-04-12 2020-10-15 田辺三菱製薬株式会社 糖尿病治療用口腔内速崩壊錠
JP2023156269A (ja) 2022-04-12 2023-10-24 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7117975B2 (ja) * 2018-10-31 2022-08-15 沢井製薬株式会社 テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209350A1 (ja) 2019-04-12 2020-10-15 田辺三菱製薬株式会社 糖尿病治療用口腔内速崩壊錠
JP2023156269A (ja) 2022-04-12 2023-10-24 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Also Published As

Publication number Publication date
TW202444369A (zh) 2024-11-16
CN119300831A (zh) 2025-01-10
JPWO2024232216A1 (https=) 2024-11-14
WO2024232216A1 (ja) 2024-11-14
TWI896097B (zh) 2025-09-01

Similar Documents

Publication Publication Date Title
US8877238B2 (en) Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
ES2617522T3 (es) Procedimiento de granulación en seco para fabricar composiciones de comprimidos de metformina y composiciones de los mismos
EP2391348B1 (en) Solid pharmaceutical composition comprising amlodipine and losartan with improved stability
JP7117975B2 (ja) テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP6446511B2 (ja) 非晶質体ソリフェナシン及び抗酸化剤を含有する固形製剤
KR20190045286A (ko) 로수바스타틴 및 에제티미브를 포함하는 제약 조성물 및 그의 제조 방법
KR20220017458A (ko) 클로미프라민 함유 약학 조성물 및 이의 제조 방법
KR101469326B1 (ko) 베포타스틴 또는 이의 약학적으로 허용가능한 염과 수불용성 염기성 물질을 포함하는 약제학적 제제
JP2023143873A (ja) ミラベグロン含有徐放性錠剤及びその製造方法、並びにミラベグロン含有徐放性錠剤の変色・膨張抑制方法
WO2006008512A2 (en) Anti-histaminic composition
US7959948B2 (en) Pharmaceutical composition of quetiapine fumarate
JP7799904B2 (ja) テネリグリプチン含有製剤
KR20170055211A (ko) 무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법
EP2101742B1 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
JP7518316B1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
WO2012080703A1 (en) Pharmaceutical composition comprising imatinib
WO2024171708A1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
KR20210096162A (ko) 의약 조성물
KR20160014619A (ko) 공-결정체 형태로 아고멜라틴을 포함하는 아고멜라틴 제형
CN119074728A (zh) 用于高血压治疗的多重释放组合物
JP2018177789A (ja) コハク酸ソリフェナシン含有固形医薬組成物
EP3505158A1 (en) Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
JP7271869B2 (ja) レボセチリジン含有錠剤
EP4260848A1 (en) Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
JP7608444B2 (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251226

R150 Certificate of patent or registration of utility model

Ref document number: 7799904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150